An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Blade Therapeutics, a clinical-stage biopharmaceutical company, announced that Dr. Wendye Robbins will participate in the panel discussion "Drug Development in Pulmonary Medicine" on August 9, 2022, at the BTIG Biotechnology Conference in New York City. The company focuses on developing treatments for fibrotic and neurodegenerative diseases, with its lead drug, cudetaxestat, expected to enter phase 2 trials for idiopathic pulmonary fibrosis. Blade Therapeutics is positioned to deliver innovative therapies targeting key biological pathways integral to fibrosis and neurodegeneration.
Positive
None.
Negative
None.
SAN FRANCISCO--(BUSINESS WIRE)--
Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will participate in the “Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need” panel discussion on Tuesday, August 9, 2022, 1:00 pm (ET), during the 2022 BTIG Biotechnology Conference, August 8 – 9, in New York City. Blade’s lead investigational medicine is cudetaxestat, a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial in patients with idiopathic pulmonary fibrosis.
This conference is being hosted by BTIG, a global financial services firm specializing in institutional trading, investment banking, research, and related brokerage services. BTIG’s Corporate Access program hosts client events across the consumer, digital assets, energy and infrastructure, financials, healthcare, real estate, and technology sectors. To join the conference, email info@btig.com.
About Blade Therapeutics
Blade Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating, incurable fibrotic and neurodegenerative diseases. The company has deep expertise in novel biological pathways – including autotaxin / LPA and calpain biology – that are foundational to cell- and tissue-damage responses associated with fibrosis and neurodegeneration. Blade’s focused approach offers the potential to produce disease-modifying, life-saving therapies. Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and an inhibitor of dimeric calpains. Visit www.blademed.com for more information and follow Blade on LinkedIn.
What is Blade Therapeutics focusing on at the BTIG Biotechnology Conference?
Blade Therapeutics is focusing on drug development for pulmonary medicine, particularly highlighting their lead investigational medicine, cudetaxestat.
When is the panel discussion featuring Dr. Wendye Robbins?
The panel discussion featuring Dr. Wendye Robbins is scheduled for August 9, 2022, at 1:00 PM ET.
What is the significance of cudetaxestat in Blade Therapeutics' pipeline?
Cudetaxestat is Blade Therapeutics' lead investigational medicine, a non-competitive autotaxin inhibitor expected to enter phase 2 trials for idiopathic pulmonary fibrosis.
Where is the BTIG Biotechnology Conference taking place?
The BTIG Biotechnology Conference is taking place in New York City on August 8 and 9, 2022.
What kind of diseases does Blade Therapeutics aim to treat?
Blade Therapeutics aims to treat debilitating fibrotic and neurodegenerative diseases.
